At the conclusion of the inspection, the US FDA issued a Form 483, listing 11 observations. Aurobindo Pharma characterised ...

Science 37, a leader in enhancing patient access to clinical trials, today announced the successful completion of its second FDA inspection, reaffirming the quality of its Direct-to-Patient Site for ...

Shilpa Pharma Lifesciences has successfully passed a U.S. FDA inspection for its Unit-2 facility in Raichur, India, with no 483 observations.

US FDA inspects Science 37’s Direct-to-Patient Site for clinical research in phase 3 asthma trial; no objectionable conditions noted: Morrisville, N.C. Thursday, April 10, 2025, ...

Aurobindo Pharma's U.S. plant receives 11 observations from FDA, no impact on operations, response to be submitted.

The Indian stock market closed with significant gains as global cues propelled frontline indices up by 2%. The Sensex jumped ...

Hyderabad: Aurobindo Pharma has announced that the United States Food and Drug Administration (USFDA) has issued 11 ...

IMPACT OF STAFF CUTS — Job cuts at the FDA could threaten the yearslong effort to return the agency’s inspections of foreign manufacturing plants to pre-pandemic levels. While the Trump ...

Aurobindo Pharma received a Form 483 with 11 observations from the USFDA for its Raleigh plant in North Carolina. The company ...

Aurobindo Pharma Ltd on Friday said the US health regulator has issued a Form 483 with 11 observations to the Raleigh plant ...